Results 141 to 150 of about 187,458 (237)
European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley +1 more source
Iranian Journal of Allergy, Asthma and Immunology, 2004 X-linked agammaglobulinemia (XLA) is an immunodeficiency caused by mutations in the Bruton tyrosine kinase (Btk) gene. In order to identify the mutations in Btk gene in Iranian patients with antibody deficiency, 13 male patients with an XLA phenotype ...
"Asghar Aghamohammadi +11 more
doaj
European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta +10 more
wiley +1 more source
Primary immunodeficiency in Hong Kong and the use of genetic analysis for diagnosis [PDF]
, 2005 Objectives. To review the management of primary immunodeficiency and discuss recent advances in genetic analysis. Design. Retrospective study. Setting. University teaching hospital, Hong Kong. Patients.
Chan, KW +4 more
core
Journal of Experimental Medicine, 1996 Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease called X-linked agammaglobulinemia, in which there is a profound decrease of mature B cells due to a block in B cell development.
Minoru Takata, Tomohiro Kurosaki
semanticscholar +1 more source
DNA methyltransferase inhibitors in hematological malignancies and solid tumors
International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger +3 more
wiley +1 more source
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
Kinases and PhosphatasesBruton’s tyrosine kinase (BTK) is a key signaling molecule involved in both hematological malignancies and solid tumors. In B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), BTK mediates B-cell receptor ...
Zahraa Qusairy, Miran Rada
doaj +1 more source
The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]
, 2019 Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
New England Journal of Medicine, 2014 J. Woyach +24 more
semanticscholar +1 more source
From phagocytosis to metaforosis: calcineurin's deadly role in innate processing of fungi [PDF]
, 2018 Armstrong-James, D +3 more
core +3 more sources